Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Histological Evaluation of the Local Soft Tissue Reaction After Implanting Resorbable and Non-resorbable Monofilament Fibers.

Żywicka B, Szymonowicz M, Bryła D, Rybak Z.

Polim Med. 2016 Jul-Dec;46(2):135-143. doi: 10.17219/pim/68618.

2.
3.

Growth patterns and morphology of fine roots of size-controlling and invigorating peach rootstocks.

Basile B, Bryla DR, Salsman ML, Marsal J, Cirillo C, Johnson RS, Dejong TM.

Tree Physiol. 2007 Feb;27(2):231-41.

PMID:
17241965
4.

Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children.

Canh DG, Lin FY, Thiem VD, Trach DD, Trong ND, Mao ND, Hunt S, Schneerson R, Robbins JB, Chu C, Shiloach J, Bryla DA, Bonnet MC, Schulz D, Szu SC.

Infect Immun. 2004 Nov;72(11):6586-8.

5.

Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children.

Mai NL, Phan VB, Vo AH, Tran CT, Lin FY, Bryla DA, Chu C, Schiloach J, Robbins JB, Schneerson R, Szu SC.

N Engl J Med. 2003 Oct 2;349(14):1390-1. No abstract available.

PMID:
14523155
6.
7.

The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children.

Lin FY, Ho VA, Khiem HB, Trach DD, Bay PV, Thanh TC, Kossaczka Z, Bryla DA, Shiloach J, Robbins JB, Schneerson R, Szu SC.

N Engl J Med. 2001 Apr 26;344(17):1263-9.

8.

The epidemiology of typhoid fever in the Dong Thap Province, Mekong Delta region of Vietnam.

Lin FY, Vo AH, Phan VB, Nguyen TT, Bryla D, Tran CT, Ha BK, Dang DT, Robbins JB.

Am J Trop Med Hyg. 2000 May;62(5):644-8.

PMID:
11289678
9.

Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel.

Passwell JH, Harlev E, Ashkenazi S, Chu C, Miron D, Ramon R, Farzan N, Shiloach J, Bryla DA, Majadly F, Roberson R, Robbins JB, Schneerson R.

Infect Immun. 2001 Mar;69(3):1351-7.

11.

Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis.

Taranger J, Trollfors B, Lagergård T, Sundh V, Bryla DA, Schneerson R, Robbins JB.

J Infect Dis. 2000 Mar;181(3):1010-3.

PMID:
10720524
12.

Phase 1 and phase 2 studies of Salmonella enterica serovar paratyphi A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers, and 2- to 4-year-old children in Vietnam.

Konadu EY, Lin FY, Hó VA, Thuy NT, Van Bay P, Thanh TC, Khiem HB, Trach DD, Karpas AB, Li J, Bryla DA, Robbins JB, Szu SC.

Infect Immun. 2000 Mar;68(3):1529-34.

13.

Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam.

Kossaczka Z, Lin FY, Ho VA, Thuy NT, Van Bay P, Thanh TC, Khiem HB, Trach DD, Karpas A, Hunt S, Bryla DA, Schneerson R, Robbins JB, Szu SC.

Infect Immun. 1999 Nov;67(11):5806-10.

14.

Treatment with succinic anhydride improves the immunogenicity of Shigella flexneri type 2a O-specific polysaccharide-protein conjugates in mice.

Pavliakova D, Chu C, Bystricky S, Tolson NW, Shiloach J, Kaufman JB, Bryla DA, Robbins JB, Schneerson R.

Infect Immun. 1999 Oct;67(10):5526-9.

15.

Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children.

Ashkenazi S, Passwell JH, Harlev E, Miron D, Dagan R, Farzan N, Ramon R, Majadly F, Bryla DA, Karpas AB, Robbins JB, Schneerson R.

J Infect Dis. 1999 Jun;179(6):1565-8.

PMID:
10228084
16.

Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis.

Trollfors B, Taranger J, Lagergård T, Sundh V, Bryla DA, Schneerson R, Robbins JB.

Clin Infect Dis. 1999 Mar;28(3):552-9.

PMID:
10194077
17.

Immunity to pertussis. Not all virulence factors are protective antigens.

Robbins JB, Schneerson R, Bryla DA, Trollfors B, Taranger J, Lagergård T.

Adv Exp Med Biol. 1998;452:207-18. Review.

PMID:
9889975
18.

Measurement of human serum IgG antibodies or a surrogate is sufficient to standardize (predict efficacy) vaccines.

Robbins JB, Schneerson R, Szu SC, Bryla DA, Lin FY.

Dev Biol Stand. 1998;95:221-2. No abstract available.

PMID:
9855435
19.

Standardization may suffice for licensure of conjugate vaccines.

Robbins JB, Schneerson R, Szu SC, Bryla DA, Lin FY, Gotschlich EC.

Dev Biol Stand. 1998;95:161-7. Review.

PMID:
9855427
20.

Phase 1 evaluation of Vibrio cholerae O1, serotype Inaba, polysaccharide-cholera toxin conjugates in adult volunteers.

Gupta RK, Taylor DN, Bryla DA, Robbins JB, Szu SC.

Infect Immun. 1998 Jul;66(7):3095-9.

21.

Immunization of children with pertussis toxoid decreases spread of pertussis within the family.

Trollfors B, Taranger J, Lagergård T, Sundh V, Bryla DA, Schneerson R, Robbins JB.

Pediatr Infect Dis J. 1998 Mar;17(3):196-9.

PMID:
9535245
22.
23.

Synthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker.

Kossaczka Z, Bystricky S, Bryla DA, Shiloach J, Robbins JB, Szu SC.

Infect Immun. 1997 Jun;65(6):2088-93.

24.

Efficacy of a monocomponent pertussis toxoid vaccine after household exposure to pertussis.

Trollfors B, Taranger J, Lagergård T, Lind L, Sundh V, Zackrisson G, Bryla DA, Robbins JB.

J Pediatr. 1997 Apr;130(4):532-6.

PMID:
9108848
25.

Unchanged efficacy of a pertussis toxoid vaccine throughout the two years after the third vaccination of infants.

Taranger J, Trollfors B, Lagergård T, Lind L, Sundh V, Zackrisson G, Bryla DA, Robbins JB.

Pediatr Infect Dis J. 1997 Feb;16(2):180-4.

PMID:
9041597
27.

Safety and immunogenicity of Staphylococcus aureus type 5 capsular polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugate vaccine in patients on hemodialysis.

Welch PG, Fattom A, Moore J Jr, Schneerson R, Shiloach J, Bryla DA, Li X, Robbins JB.

J Am Soc Nephrol. 1996 Feb;7(2):247-53.

29.

Prevention of systemic infections caused by group B streptococcus and Staphylococcus aureus by multivalent polysaccharide-protein conjugate vaccines.

Robbins JB, Schneerson R, Vann WF, Bryla DA, Fattom A.

Ann N Y Acad Sci. 1995 May 31;754:68-82. Review. No abstract available.

PMID:
7625682
30.
31.

Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines.

Szu SC, Taylor DN, Trofa AC, Clements JD, Shiloach J, Sadoff JC, Bryla DA, Robbins JB.

Infect Immun. 1994 Oct;62(10):4440-4.

32.

Immunogenicity of two types of Shigella flexneri 2a O-specific polysaccharide-tetanus toxoid conjugates.

Polotsky VY, Schneerson R, Bryla D, Robbins JB.

Ann N Y Acad Sci. 1994 Aug 15;730:359-60. No abstract available.

PMID:
8080210
33.
35.

Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A.

Fattom A, Schneerson R, Watson DC, Karakawa WW, Fitzgerald D, Pastan I, Li X, Shiloach J, Bryla DA, Robbins JB.

Infect Immun. 1993 Mar;61(3):1023-32.

36.

Synthesis of a conjugate vaccine composed of pneumococcus type 14 capsular polysaccharide bound to pertussis toxin.

Schneerson R, Levi L, Robbins JB, Bryla DM, Schiffman G, Lagergard T.

Infect Immun. 1992 Sep;60(9):3528-32. Erratum in: Infect Immun 1992 Oct;60(10):4443.

37.
38.
39.

Evaluation of monophosphoryl lipid A (MPL) as an adjuvant. Enhancement of the serum antibody response in mice to polysaccharide-protein conjugates by concurrent injection with MPL.

Schneerson R, Fattom A, Szu SC, Bryla D, Ulrich JT, Rudbach JA, Schiffman G, Robbins JB.

J Immunol. 1991 Oct 1;147(7):2136-40.

PMID:
1918948
40.

Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity.

Devi SJ, Schneerson R, Egan W, Ulrich TJ, Bryla D, Robbins JB, Bennett JE.

Infect Immun. 1991 Oct;59(10):3700-7.

41.

Persistence of serum antibodies elicited by Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in infants vaccinated at 3, 5 and 12 months of age.

Claesson BA, Schneerson R, Lagergård T, Trollfors B, Taranger J, Johansson J, Bryla D, Robbins JB.

Pediatr Infect Dis J. 1991 Aug;10(8):560-4.

PMID:
1891286
42.

Intelligence at six years in relation to neonatal bilirubin levels: follow-up of the National Institute of Child Health and Human Development Clinical Trial of Phototherapy.

Scheidt PC, Graubard BI, Nelson KB, Hirtz DG, Hoffman HJ, Gartner LM, Bryla DA.

Pediatrics. 1991 Jun;87(6):797-805.

PMID:
2034482
43.

Clinical and immunologic responses to Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in infants injected at 3, 5, 7, and 18 months of age.

Parke JC Jr, Schneerson R, Reimer C, Black C, Welfare S, Bryla D, Levi L, Pavliakova D, Cramton T, Schulz D, et al.

J Pediatr. 1991 Feb;118(2):184-90.

PMID:
1993943
45.
46.

Serum antibody response in adult volunteers elicited by injection of Streptococcus pneumoniae type 12F polysaccharide alone or conjugated to diphtheria toxoid.

Fattom A, Lue C, Szu SC, Mestecky J, Schiffman G, Bryla D, Vann WF, Watson D, Kimzey LM, Robbins JB, et al.

Infect Immun. 1990 Jul;58(7):2309-12.

47.
48.

Studies on Pneumococcus vaccine alone or mixed with DTP and on Pneumococcus type 6B and Haemophilus influenzae type b capsular polysaccharide-tetanus toxoid conjugates in two- to five-year-old children with sickle cell anemia.

Sarnaik S, Kaplan J, Schiffman G, Bryla D, Robbins JB, Schneerson R.

Pediatr Infect Dis J. 1990 Mar;9(3):181-6. Erratum in: Pediatr Infect Dis J 1990 May;9(5):308.

PMID:
2336298
49.
50.

Protective levels of serum antibodies stimulated in infants by two injections of Haemophilus influenzae type b capsular polysaccharide-tetanus toxoid conjugate.

Claesson BA, Schneerson R, Robbins JB, Johansson J, Lagergard T, Taranger J, Bryla D, Levi L, Cramton T, Trollfors B.

J Pediatr. 1989 Jan;114(1):97-100. No abstract available.

PMID:
2783345

Supplemental Content

Support Center